The main scientific goal of this project is to improve the diffusion of NAMs through the bacterial envelope of S. aureus and consequently be a step closer to the use of NAMs as novel antibacterial nano-based drug. For that, we propose to develop novel nanotech-double functionalized particles to transport the NAMs to promote the decline of S. aureus related diseases. As many technological challenges hamper the development of antibacterial strategies, nanotechnology seems to be a suitable approach to overcome these challenges and allow the development of novel functional therapeutic strategy. Thus, this plan focuses on the use of NAMs encapsulated into PLGA NPs. The encapsulation of these molecules in NPs with a modified surface will allow to increase their specificity and ability to enter in the bacteria. This nanostrategy is deigned to be used by intravenous administration. However, in the future, other routs of administration, such as oral administration, could be a possibility. Additionally, this strategy could be applied for the treatment of other bacterial infections caused from different bacteria, through the use of different NAMs and other phage proteins specific for other bacteria.
The overall objective (O) will be achieved through 4 specific ones:
O.1: To select appropriate NAMs against S. aureus
O.2: To product and in vitro characterization of reproducible PLGA NPs containing NAMs
O.3: To modify the PLGA NPs surface to increase their specificity and uptake in bacteria through the use of phage proteins and CPPs O.4: To evaluate the in vitro efficacy of the nanocarrier to deliver the NAMs into bacteria |